Jounce Therapeutics to Present at Upcoming Investor Conferences in September
August 29 2018 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Jounce management will present at three upcoming investor
conferences:
- H.C. Wainwright 20th Annual Global Investment
Conference at 11:15 a.m. ET on Wednesday, September 5,
2018 in New York, NY
- Baird 2018 Global Healthcare Conference at
3:45 p.m. ET on Wednesday, September 5, 2018 in New York, NY
- 2018 Wells Fargo Healthcare Conference at
11:30 a.m. ET on Thursday, September 6, 2018 in Boston, MA
A live webcast of each presentation will be available by
visiting “Events and Presentations” in the Investors and Media
section of Jounce’s website at www.jouncetx.com. A replay of the
webcasts will be archived for 30 days following each
presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right immunotherapy to the right patient.
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody
that binds to and activates ICOS and is currently conducting the
Phase 1/2 ICONIC trial. For more information, please visit
www.jouncetx.com.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Gina Nugent The Yates Network
(617) 460-3579 gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024